<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00647088</url>
  </required_header>
  <id_info>
    <org_study_id>P070141</org_study_id>
    <nct_id>NCT00647088</nct_id>
  </id_info>
  <brief_title>Genetic of Aortic Valve Stenosis - Clinical and Therapeutic Implications</brief_title>
  <acronym>GENERAC</acronym>
  <official_title>Genetic of Aortic Valve Stenosis - Clinical and Therapeutic Implications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pathophysiology of Aortic Valve Stenosis remains poorly known. The aim of the present study&#xD;
      is to identify genetic factors involved in this disease using a case control trial design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aortic valve stenosis (AS) is the most common valvular disease and the second most common&#xD;
      indication for cardiac surgery in Western countries. AS has long been considered as a passive&#xD;
      and degenerative process. Recent data challenged this concept, showing that AS is an active&#xD;
      and highly regulated process with some similarities to atherosclerosis. However,&#xD;
      pathophysiology of AS remains poorly understood and preliminary data suggest that genetic&#xD;
      factors may be involved. The aim of the present study is to identify genetic factors involved&#xD;
      in this disease using a case control trial design (1000 patients with AS and 1500 controls&#xD;
      with no evidence of valve disease). For all patients and controls, blood samples including&#xD;
      DNA and echocardiography will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of genetic polymorphisms of fetuin-A, matrix-GLA protein, vitamin D receptor</measure>
    <time_frame>end of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of other genetic polymorphisms</measure>
    <time_frame>End of the Study</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2200</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>aortic stenosis</arm_group_label>
    <description>various age and disease severity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Controls free of valvular disease</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples DNA Tissue valve&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        case control study Case = patients with aortic valve stenosis Controls = participants free&#xD;
        of aortic valve stenosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients:&#xD;
&#xD;
        Inclusion criteria :&#xD;
&#xD;
          -  Age &gt;=18 years&#xD;
&#xD;
          -  Pure isolated degenerative aortic valve stenosis&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Rheumatic, congenital or post-radiation aortic stenosis&#xD;
&#xD;
          -  Severe renal insufficiency (clearance &lt; 30 ml/min)&#xD;
&#xD;
          -  Aortic insufficiency &gt; or = grade 2/4&#xD;
&#xD;
          -  Other valve disease &gt; or = grade 2/4&#xD;
&#xD;
        Controls&#xD;
&#xD;
        Inclusion criteria :&#xD;
&#xD;
        - Age &gt;=18 years&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Known first degree relative with aortic valve stenosis&#xD;
&#xD;
          -  Severe renal insufficiency (clearance &lt; 30 ml/min)&#xD;
&#xD;
          -  Any valve disease &gt; or = grade 2/4&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Messika-Zeitoun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Paris, Bichat Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David MESSIKA-ZEITOUN, MD</last_name>
      <phone>01 40 25 66 01</phone>
      <phone_ext>00 33</phone_ext>
      <email>david.messika-zeitoun@bch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>David Messika-Zeitoun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2008</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Valve stenosis</keyword>
  <keyword>Genetic</keyword>
  <keyword>Mineralisation inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

